Kombination af aliskiren og losartan hos patienter med type 2-diabetes og nefropati - Sekundaerpublikation

Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg

Kombination af aliskiren og losartan hos patienter med type 2-diabetes og nefropati - Sekundaerpublikation

Translated title of the contribution: Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication

Hans-Henrik Parving, Frederik Persson, Julia B Lewis, Edmund J Lewis, Norman K Hollenberg

3 Citations (Scopus)

Abstract

We evaluated the renoprotective effects of adding aliskiren to treatment with losartan in hypertensive patients with type 2 diabetes and nephropathy. A total of 599 patients were randomized to six months of treatment with placebo or aliskiren in addition to losartan 100 mg and optimal antihypertensive therapy. The primary outcome was a reduction in the urinary albumin-creatinine ratio. Aliskiren 300 mg daily reduced the mean urinary albumin-creatinine ratio by 20% (p < 0.001) compared with placebo. The number of adverse events was similar between groups. Aliskiren is renoprotective independently of its blood pressure lowering effect.

Translated title of the contribution	Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	171
Issue number	11
Pages (from-to)	881-4
Number of pages	4
ISSN	0041-5782
Publication status	Published - 9 Mar 2009

Keywords

English Abstract
Journal Article

Cite this

@article{5ba26ece290c4d69b1f38b12a4b5455b,

title = "Kombination af aliskiren og losartan hos patienter med type 2-diabetes og nefropati - Sekundaerpublikation",

abstract = "We evaluated the renoprotective effects of adding aliskiren to treatment with losartan in hypertensive patients with type 2 diabetes and nephropathy. A total of 599 patients were randomized to six months of treatment with placebo or aliskiren in addition to losartan 100 mg and optimal antihypertensive therapy. The primary outcome was a reduction in the urinary albumin-creatinine ratio. Aliskiren 300 mg daily reduced the mean urinary albumin-creatinine ratio by 20\% (p < 0.001) compared with placebo. The number of adverse events was similar between groups. Aliskiren is renoprotective independently of its blood pressure lowering effect.",

keywords = "English Abstract, Journal Article",

author = "Hans-Henrik Parving and Frederik Persson and Lewis, \{Julia B\} and Lewis, \{Edmund J\} and Hollenberg, \{Norman K\}",

year = "2009",

month = mar,

day = "9",

language = "Dansk",

volume = "171",

pages = "881--4",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "11",

}

TY - JOUR

T1 - Kombination af aliskiren og losartan hos patienter med type 2-diabetes og nefropati - Sekundaerpublikation

AU - Parving, Hans-Henrik

AU - Persson, Frederik

AU - Lewis, Julia B

AU - Lewis, Edmund J

AU - Hollenberg, Norman K

PY - 2009/3/9

Y1 - 2009/3/9

N2 - We evaluated the renoprotective effects of adding aliskiren to treatment with losartan in hypertensive patients with type 2 diabetes and nephropathy. A total of 599 patients were randomized to six months of treatment with placebo or aliskiren in addition to losartan 100 mg and optimal antihypertensive therapy. The primary outcome was a reduction in the urinary albumin-creatinine ratio. Aliskiren 300 mg daily reduced the mean urinary albumin-creatinine ratio by 20% (p < 0.001) compared with placebo. The number of adverse events was similar between groups. Aliskiren is renoprotective independently of its blood pressure lowering effect.

AB - We evaluated the renoprotective effects of adding aliskiren to treatment with losartan in hypertensive patients with type 2 diabetes and nephropathy. A total of 599 patients were randomized to six months of treatment with placebo or aliskiren in addition to losartan 100 mg and optimal antihypertensive therapy. The primary outcome was a reduction in the urinary albumin-creatinine ratio. Aliskiren 300 mg daily reduced the mean urinary albumin-creatinine ratio by 20% (p < 0.001) compared with placebo. The number of adverse events was similar between groups. Aliskiren is renoprotective independently of its blood pressure lowering effect.

KW - English Abstract

KW - Journal Article

UR - https://www.scopus.com/pages/publications/70449650949

M3 - Tidsskriftartikel

C2 - 19291865

SN - 0041-5782

VL - 171

SP - 881

EP - 884

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 11

ER -

Kombination af aliskiren og losartan hos patienter med type 2-diabetes og nefropati - Sekundaerpublikation

Abstract

Keywords

Other files and links

Fingerprint

Cite this